Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2004;110:2869-2874
Published online before print October 25, 2004, doi: 10.1161/01.CIR.0000146889.46519.27
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
110/18/2869    most recent
01.CIR.0000146889.46519.27v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nozaki, N.
Right arrow Articles by Kubota, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nozaki, N.
Right arrow Articles by Kubota, I.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Cardiomyopathy
Hazardous Substances DB
*DOXORUBICIN
Related Collections
Right arrow Other heart failure
Right arrow Myocardial cardiomyopathy disease
Right arrow Oxidant stress
Right arrow Apoptosis

(Circulation. 2004;110:2869-2874.)
© 2004 American Heart Association, Inc.


Heart Failure

Modulation of Doxorubicin-Induced Cardiac Dysfunction in Toll-Like Receptor-2–Knockout Mice

Naoki Nozaki, MD, PhD*; Tetsuro Shishido, MD, PhD*; Yasuchika Takeishi, MD, PhD; Isao Kubota, MD, PhD

From the First Department of Internal Medicine, Yamagata University School of Medicine, Yamagata, Japan.

Correspondence to Yasuchika Takeishi, MD, PhD, First Department of Internal Medicine, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata, Japan 990-9585. E-mail takeishi{at}med.id.yamagata-u.ac.jp

Received September 19, 2003; de novo received February 14, 2004; revision received June 4, 2004; accepted June 7, 2004.

Background— Toll-like receptors (TLRs) are members of the interleukin-1 receptor family and are involved in the responsiveness to pathogen-associated molecular patterns. Recent studies have demonstrated that TLRs are activated by endogenous signals, such as heat shock proteins and oxidative stress, which may contribute to congestive heart failure. Oxidative stress is one of the major factors in doxorubicin (Dox)-induced cardiac dysfunction. Thus, we hypothesized that TLRs contribute to the pathogenesis of Dox-induced cardiac dysfunction.

Methods and Results— Cardiac dysfunction was induced by a single injection of Dox (20 mg/kg IP) into wild-type (WT) mice and TLR-2–knockout (KO) mice. Five days after Dox injection, left ventricular dimension at end-diastole was smaller and fractional shortening was higher in KO mice compared with WT mice (P<0.01). Nuclear factor-{kappa}B activation and production of proinflammatory cytokines after Dox were suppressed in KO mice compared with WT mice (P<0.01). The numbers of TUNEL-positive nuclei and Dox-induced caspase-3 activation were less in KO mice than in WT mice (P<0.01). Survival rate was significantly higher in KO mice than in WT mice 10 days after Dox injection (46% vs 11%, P<0.05).

Conclusions— These findings suggest that TLR-2 may play a role in the regulation of inflammatory and apoptotic mediators in the heart after Dox administration.


Key Words: apoptosis • cardiomyopathy • receptors • interleukins • fee radicals




This article has been cited by other articles:


Home page
J. Immunol.Home page
A. Riad, S. Jager, M. Sobirey, F. Escher, A. Yaulema-Riss, D. Westermann, A. Karatas, M. M. Heimesaat, S. Bereswill, D. Dragun, et al.
Toll-Like Receptor-4 Modulates Survival by Induction of Left Ventricular Remodeling after Myocardial Infarction in Mice
J. Immunol., May 15, 2008; 180(10): 6954 - 6961.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Bien, A. Riad, C. A. Ritter, M. Gratz, F. Olshausen, D. Westermann, M. Grube, T. Krieg, S. Ciecholewski, S. B. Felix, et al.
The Endothelin Receptor Blocker Bosentan Inhibits Doxorubicin-Induced Cardiomyopathy
Cancer Res., November 1, 2007; 67(21): 10428 - 10435.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Mukhopadhyay, S. Batkai, M. Rajesh, N. Czifra, J. Harvey-White, G. Hasko, Z. Zsengeller, N. P. Gerard, L. Liaudet, G. Kunos, et al.
Pharmacological Inhibition of CB1 Cannabinoid Receptor Protects Against Doxorubicin-Induced Cardiotoxicity
J. Am. Coll. Cardiol., August 7, 2007; 50(6): 528 - 536.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. G. Neilan, S. L. Blake, F. Ichinose, M. J. Raher, E. S. Buys, D. S. Jassal, E. Furutani, T. M. Perez-Sanz, A. Graveline, S. P. Janssens, et al.
Disruption of Nitric Oxide Synthase 3 Protects Against the Cardiac Injury, Dysfunction, and Mortality Induced by Doxorubicin
Circulation, July 31, 2007; 116(5): 506 - 514.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Favre, P. Musette, V. Douin-Echinard, K. Laude, J.-P. Henry, J.-F. Arnal, C. Thuillez, and V. Richard
Toll-Like Receptors 2-Deficient Mice Are Protected Against Postischemic Coronary Endothelial Dysfunction
Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1064 - 1071.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
T. G. Neilan, D. S. Jassal, T. M. Perez-Sanz, M. J. Raher, A. D. Pradhan, E. S. Buys, F. Ichinose, D. B. Bayne, E. F. Halpern, A. E. Weyman, et al.
Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury
Eur. Heart J., August 1, 2006; 27(15): 1868 - 1875.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. Li, R. Y. T. Sung, W. Z. Huang, M. Yang, N. H. Pong, S. M. Lee, W. Y. Chan, H. Zhao, M. Y. To, T. F. Fok, et al.
Thrombopoietin Protects Against In Vitro and In Vivo Cardiotoxicity Induced by Doxorubicin
Circulation, May 9, 2006; 113(18): 2211 - 2220.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Arimoto, Y. Takeishi, H. Takahashi, T. Shishido, T. Niizeki, Y. Koyama, R. Shiga, N. Nozaki, O. Nakajima, K. Nishimaru, et al.
Cardiac-Specific Overexpression of Diacylglycerol Kinase {zeta} Prevents Gq Protein-Coupled Receptor Agonist-Induced Cardiac Hypertrophy in Transgenic Mice
Circulation, January 3, 2006; 113(1): 60 - 66.
[Abstract] [Full Text] [PDF]